Quick Answer
PALISADE BIO, INC. reported Net Income Loss of -$16.78 million for the year ending 2025.
- PALISADE BIO, INC. showed a decrease of -16.2% in Net Income Loss from 2024 to 2025.
- This data is from PALISADE BIO, INC.'s annual report (Form 10-K), filed with the SEC on March 20, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$5.92 million | Q2 2014: -$6.75 million | Q3 2014: -$4.46 million | Q4 2014: -$5.50 million | Q1 2015: -$5.05 million | Q2 2015: -$5.45 million | Q3 2015: -$5.64 million | Q4 2015: -$4.77 million | Q1 2016: -$6.61 million | Q2 2016: -$3.85 million | Q3 2016: -$5.22 million | Q1 2017: -$7.57 million | Q2 2017: -$4.65 million | Q3 2017: -$133.8 thousand | Q1 2018: -$2.15 million | Q2 2018: -$627.0 thousand | Q3 2018: -$1.83 million | Q1 2019: -$3.11 million | Q2 2019: -$1.44 million | Q3 2019: -$1.76 million | Q1 2020: -$2.38 million | Q2 2020: -$1.85 million | Q3 2020: -$1.84 million | Q1 2021: -$4.03 million | Q2 2021: -$31.75 million | Q3 2021: $8.09 million | Q1 2022: -$4.21 million | Q2 2022: -$2.34 million | Q3 2022: -$3.99 million | Q1 2023: -$2.34 million | Q2 2023: -$3.39 million | Q3 2023: -$3.60 million | Q1 2024: -$3.53 million | Q2 2024: -$4.08 million | Q3 2024: -$3.49 million | Q1 2025: -$2.23 million | Q2 2025: -$2.78 million | Q3 2025: -$2.87 million.
- Over the full 17 years of available data (2009 to 2025), PALISADE BIO, INC.'s Net Income Loss has declined by 61.9%.
- Historical annual values: Fiscal year 2025: -$16.78 million | Fiscal year 2024: -$14.44 million | Fiscal year 2023: -$12.30 million | Fiscal year 2022: -$14.26 million | Fiscal year 2021: -$26.62 million | Fiscal year 2020: -$10.32 million | Fiscal year 2019: -$8.35 million | Fiscal year 2018: -$4.92 million | Fiscal year 2017: -$15.67 million | Fiscal year 2016: -$21.07 million | Fiscal year 2015: -$20.90 million | Fiscal year 2014: -$22.63 million | Fiscal year 2013: -$19.83 million | Fiscal year 2012: -$10.12 million | Fiscal year 2011: -$12.52 million | Fiscal year 2010: -$18.39 million | Fiscal year 2009: -$10.36 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: